Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.

Oncology research - 29 Mar 2019

Wei Xiaoting, Mao Lili, Chi Zhihong, Sheng Xinan, Cui Chuanliang, Kong Yan, Dai Jie, Wang Xuan, Li Siming, Tang Bixia, Lian Bin, Yan Xieqiao, Bai Xue, Zhou Li, Guo Jun, Si Lu

Abstract excerpt

Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Melanoma

Share to Neoplasm Staging

Share to Proportional Hazards Models

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 30075827
DOI: 10.3727/096504018X15331163433914
PMCID: PMC7848371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.PMID 30075827Read ↗

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.Semantic proximity Read ↗

Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).Semantic proximity Read ↗

C-kit-mutated melanomas: the Chinese experience.Semantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

Complete response in a melanoma patient treated with imatinib.Semantic proximity Read ↗

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.Semantic proximity Read ↗

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)Semantic proximity Read ↗

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13).Semantic proximity Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

Another Option in Our KIT of Effective Therapies for Advanced MelanomaSemantic proximity Read ↗

Imatinib targeting of KIT-mutant oncoprotein in melanoma.Semantic proximity Read ↗

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.